Compare TMDX & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMDX | CPRX |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.4B |
| IPO Year | 2019 | 2006 |
| Metric | TMDX | CPRX |
|---|---|---|
| Price | $67.93 | $31.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $148.22 | $35.00 |
| AVG Volume (30 Days) | 1.2M | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 382.18 | 28.24 |
| EPS | 0.20 | ★ 1.68 |
| Revenue | ★ $605,494,000.00 | $119,072,803.00 |
| Revenue This Year | $24.25 | $9.20 |
| Revenue Next Year | $18.75 | $10.51 |
| P/E Ratio | $362.75 | ★ $18.54 |
| Revenue Growth | ★ 37.13 | 16.39 |
| 52 Week Low | $70.00 | $19.05 |
| 52 Week High | $156.00 | $32.56 |
| Indicator | TMDX | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 19.80 | 73.25 |
| Support Level | N/A | $22.41 |
| Resistance Level | $131.86 | $32.56 |
| Average True Range (ATR) | 5.31 | 1.30 |
| MACD | -3.88 | 0.30 |
| Stochastic Oscillator | 0.17 | 80.10 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.